2. Membrane Transporter/Ion Channel Apoptosis
  3. Sodium Channel Ferroptosis
  4. Levobupivacaine hydrochloride

Levobupivacaine hydrochloride  (Synonyms: (S)-(-)-Bupivacaine monohydrochloride)

目录号: HY-B0653A 纯度: 99.98%
COA 产品使用指南

摩尔计算器

Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) 是一种长效的酰胺类局部麻醉剂。Levobupivacaine hydrochloride 通过可逆性阻断神经元钠通道 (sodium channel) 发挥麻醉镇痛作用。Levobupivacaine hydrochloride 可抑制心血管等组织的传递和传导冲动，具有一定的心脏和中枢神经毒性。Levobupivacaine hydrochloride 在体内由细胞色素P450 (CYP450) 代谢。Levobupivacaine hydrochloride 也可通过 miR-489-3p/SLC7A11 信号通路诱导胃癌铁死亡 (ferroptosis)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Levobupivacaine hydrochloride Chemical Structure

Levobupivacaine hydrochloride Chemical Structure

CAS No. : 27262-48-2

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
Free Sample (0.1 - 0.2 mg)   Apply now  
10 mM * 1 mL in DMSO ￥500
In-stock
5 mg ￥250
In-stock
10 mg ￥400
In-stock
50 mg ￥700
In-stock
100 mg ￥990
In-stock
200 mg ￥1400
In-stock
500 mg ￥2400
In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Other Forms of Levobupivacaine hydrochloride:

Levobupivacaine hydrochloride 相关抗体

Top Publications Citing Use of Products

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local anaesthetic. Levobupivacaine hydrochloride exerts anaesthetic and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer[1][2][3].

IC50 & Target

Sodium channels, Ferroptosis[1]
体外研究
(In Vitro)

Levobupivacaine (0-4 mM; 24 h) does not affect the viability of GES-1 cells but inhibits the viability of HGC27 and SGC7901 cells[2].
Levobupivacaine (2 mM; 24, 48 or 72 h) enhances Erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induces the levels of Fe2+, iron, and lipid ROS[2].
Levobupivacaine (2 mM; 24 h) enhances the expression of miR-489-3p in HGC27 and SGC7901 cells, increases the levels of Fe2+ and iron[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Levobupivacaine hydrochloride 相关抗体:

Cell Viability Assay[2]

Cell Line: GES-1, HGC27 and SGC790
Concentration: 0, 0.5, 1, 2 and 4 mM
Incubation Time: 24 h
Result: Did not affect the viability of normal gastric epithelial GES-1 cell lines but inhibited the viability of HGC27 and SGC7901 cells in a dose-dependent manner.

Cell Viability Assay[2]

Cell Line: HGC27 and SGC7901 (incubated with 5 μM erastin)
Concentration: 2 mM
Incubation Time: 24, 48 or 72 h
Result: Enhanced erastin-induced inhibitory impact on HGC27 and SGC7901 cell viabilities; induced the levels of Fe2+, iron, and lipid ROS.

RT-PCR[2]

Cell Line: HGC27 and SGC7901 (incubated with 5 μM erastin)
Concentration: 2 mM
Incubation Time: 24 h
Result: Enhanced the expression of miR-489-3p in HGC27 and SGC7901 cells, increased the levels of Fe2+ and iron.
体内研究
(In Vivo)

Levobupivacaine (40 μmol/kg; IP; once daily for 25 days) significantly inhibits SGC7901 cell growth, and enhances the lipid ROS accumulation[2].
Levobupivacaine (5 or 36 mg/kg; IP; single dosage) increases the latency to partial seizures and prevents the occurrence of generalized seizures at low dosage; reduces the latency to N-methyl-d-aspartate (NMDA)-induced seizures and increased seizure severity at high dosage[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD1 mice (30-35 g; induced epileptic seizures by injecting with NMDA)[3]
Dosage: 5 or 36 mg/kg
Administration: IP; single dosage
Result: Increased the latency to partial seizures and prevented the occurrence of generalized seizures at 5 mg/kg; reduced the latency to NMDA-induced seizures and increased seizure severity at 36 mg/kg.
Animal Model: SCID nude mice (6-8 weeks; subcutaneously injected with 5×106 SGC7901 cells)[2]
Dosage: 40 μmol/kg
Administration: IP; once daily for 25 days
Result: Significantly inhibited SGC7901 cell growth, and enhanced the lipid ROS accumulation.
Clinical Trial
分子量

324.89

Formula

C18H29ClN2O
CAS 号
性状

固体

颜色

White to off-white

中文名称

盐酸左布比卡因；左布比卡因盐酸盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO 中的溶解度 : 100 mg/mL (307.80 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H2O 中的溶解度 : ≥ 50 mg/mL (153.90 mM)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.0780 mL 15.3898 mL 30.7796 mL
5 mM 0.6156 mL 3.0780 mL 6.1559 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

In Vivo:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 3 mg/mL (9.23 mM); 澄清溶液

    此方案可获得 ≥ 3 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 30.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

    生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂： 10% DMSO    90% Corn Oil

    Solubility: ≥ 3 mg/mL (9.23 mM); 澄清溶液

    此方案可获得 ≥ 3 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。

    以 1 mL 工作液为例，取 100 μL 30.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
该产品水溶性佳，请具体参考实测 水 / PBS / Saline 中的溶解度数据。
您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。
纯度 & 产品资料
参考文献

Levobupivacaine hydrochloride 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 3.0780 mL 15.3898 mL 30.7796 mL 76.9491 mL
5 mM 0.6156 mL 3.0780 mL 6.1559 mL 15.3898 mL
10 mM 0.3078 mL 1.5390 mL 3.0780 mL 7.6949 mL
15 mM 0.2052 mL 1.0260 mL 2.0520 mL 5.1299 mL
20 mM 0.1539 mL 0.7695 mL 1.5390 mL 3.8475 mL
25 mM 0.1231 mL 0.6156 mL 1.2312 mL 3.0780 mL
30 mM 0.1026 mL 0.5130 mL 1.0260 mL 2.5650 mL
40 mM 0.0769 mL 0.3847 mL 0.7695 mL 1.9237 mL
50 mM 0.0616 mL 0.3078 mL 0.6156 mL 1.5390 mL
60 mM 0.0513 mL 0.2565 mL 0.5130 mL 1.2825 mL
80 mM 0.0385 mL 0.1924 mL 0.3847 mL 0.9619 mL
100 mM 0.0308 mL 0.1539 mL 0.3078 mL 0.7695 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Levobupivacaine27262-48-2(S)-(-)-Bupivacaine monohydrochloride盐酸左布比卡因左布比卡因盐酸盐Sodium ChannelFerroptosisNa channelsNa+ channelsanaestheticanalgesiccardiac toxicityCNS toxicityCYP450gastric cancerErastinNMDAInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Levobupivacaine hydrochloride
目录号：
HY-B0653A
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z